| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | SemE; SEMAE |
| WB Predicted band size | 85 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human SEMA3C |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是几篇与 **SEMA3C抗体** 相关的模拟参考文献示例(仅供参考，实际文献需通过学术数据库验证)：
---
1. **标题**：*SEMA3C Drives Pancreatic Cancer Metastasis by Promoting EMT and Activating ERK/MMP Signaling*
**作者**：Mazur PK, et al.
**摘要**：研究利用SEMA3C抗体检测其在胰腺癌组织中的表达，发现SEMA3C通过激活ERK/MMP通路促进上皮-间质转化(EMT)和转移，提示其作为治疗靶点的潜力。
2. **标题**：*SEMA3C as a Prognostic Biomarker in Prostate Cancer: Correlation with Androgen Receptor Signaling*
**作者**：Smith JL, et al.
**摘要**：通过免疫组化(SEMA3C抗体)分析前列腺癌患者样本，发现SEMA3C高表达与雄激素受体激活及不良预后显著相关，可能参与治疗耐药性机制。
3. **标题**：*Targeting SEMA3C in Glioblastoma: A Novel Autocrine Loop for Tumor Survival*
**作者**：Wu Q, et al.
**摘要**：研究使用SEMA3C中和抗体阻断胶质母细胞瘤细胞的自分泌信号，发现其抑制肿瘤细胞增殖并诱导凋亡，揭示了SEMA3C-Plexin受体轴的关键作用。
4. **标题**：*SEMA3C Promotes Chemoresistance in Ovarian Cancer via PI3K/AKT Pathway Activation*
**作者**：Li Y, et al.
**摘要**：通过抗体介导的SEMA3C功能抑制实验，证明其在卵巢癌中通过PI3K/AKT通路增强化疗耐药性，为联合靶向治疗提供依据。
---
**注意**：以上为模拟示例，实际文献请通过 **PubMed/Google Scholar** 以关键词 "SEMA3C antibody" 或 "SEMA3C function" 检索最新研究。
**Background of SEMA3C Antibody**
SEMA3C (Semaphorin-3C) is a secreted glycoprotein belonging to the semaphorin family, known for its role in axon guidance during neural development. Beyond the nervous system, SEMA3C regulates diverse biological processes, including cell migration, angiogenesis, immune response, and cancer progression. Structurally, it contains a conserved Sema domain, a PSI (plexin-semaphorin-integrin) domain, and an immunoglobulin-like domain, enabling interactions with receptors such as plexins and neuropilins. These interactions activate downstream signaling pathways (e.g., Rho GTPases, MAPK) to modulate cytoskeletal dynamics and gene expression.
In cancer, SEMA3C is often overexpressed in tumors (e.g., prostate, breast, pancreatic) and linked to tumor growth, metastasis, and therapy resistance by promoting angiogenesis, epithelial-mesenchymal transition (EMT), and survival signaling. SEMA3C-targeting antibodies are critical tools for studying its expression, localization, and functional roles. They enable applications like Western blotting, immunohistochemistry, and flow cytometry to assess protein levels in tissues or cell lines. Function-blocking SEMA3C antibodies are also explored for therapeutic potential, as they may inhibit tumor-promoting signaling by neutralizing SEMA3C or disrupting receptor binding.
Research on SEMA3C antibodies continues to advance their diagnostic and therapeutic utility, though challenges remain in optimizing specificity and efficacy for clinical translation.
×
